title: Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus.
abstract: Psoriasis is an autoimmune inflammatory disease that has recently been treated with a novel treatment, ustekinumab, a human monoclonal antibody that targets the Th17 pathway. Discoid lupus is a subset of chronic cutaneous lupus erythematosus. Recent studies have suggested the Th17 pathway may be involved in cutaneous lupus. We present a case of a 41-year-old man with both severe psoriasis and hypertrophic discoid lupus treated with ustekinumab. After three doses of 45 mg subcutaneous injections at day 1, week 4, and week 16, his psoriasis plaques cleared and his hypertrophic discoid lupus plaques showed moderate improvement. Following a fourth dose of 90 mg his lupus plaques showed marked improvement. Ustekinumab may be a promising therapy for this and other forms of cutaneous lupus.
authors.affiliation: University of Utah, Department of Dermatology, 30 North 1900 East 4A330, School of Medicine, SLC UT 84132, USA. daniel.winchester@hsc.utah.edu
authors.forename: D
authors.initials: D
authors.lastname: Winchester
authors.forename: K Callis
authors.initials: KC
authors.lastname: Duffin
authors.forename: C
authors.initials: C
authors.lastname: Hansen
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D006984:Hypertrophy; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D058504:Th17 Cells / Q000502:physiology; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab